Journey Medical (DERM) enters into a second licensing agreement with Maruho to develop and commercialize Qbrexza to treat hyperhidrosis in certain Asian countries. The stock surges 18.4%.
– Former FDA Associate Commissioner of External Affairs brings nearly 20 years of communications, patient advocacy and public affairs experience across government, public and private sectors –MENLO PARK, Calif. (BUSINESS WIRE) ReCode Therapeutics, a clinical-stage genetic medicines company using superior delivery.
Operator: Ladies and gentlemen, thank you for standing by. Good afternoon and welcome to the Journey Medical s First Quarter 2023 Financial Results and Corporate Update Conference Call.